1
reviewed how monoclonal antibodies against the immune checkpoint molecules cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1) and PD-ligand 1 (PD-L1) are effective in mediating tumour shrinkage in several cancer types. Drake et al. 1 also highlighted ongoing phase III clinical trials and discussed the increased antitumour activity of the combinations of these antibodies compared with blocking either checkpoint alone. However, we would like to note that regulatory T cells (T REG ) might represent another important immunological checkpoint to target in cancer immunotherapy. 2, 3 In fact, T REG that express CD4, CD25 and the forkhead protein 3 (FoxP3) can inhibit the antitumour immune response, thereby l imiting the power of cancer immunotherapies. 2 Although Drake et al. 1 did not discuss the effects of CTLA-4 and PD-1 or PD-L1 blockade on CD4 + CD25 + FoxP3 + T REG , this needs to be considered. PD-1 blockade negatively regulates intracellular FoxP3 expression in T REG . 4, 5 Specifically, Wang et al. 4 showed that PD-1 blockade leads to the downregulation of intracellular FoxP3 expression in T REG of patients with melanoma, suggesting that PD-1 is implicated in the regulation of T REG function. Furthermore, Sharma et al. 5 demonstrated that the ability of T REG to suppress target T-cell proliferation is abrogated by PD-1 and PD-L1 antibodies. The effect of CTLA-4 blockade on T REG is less clear. 6, 7 CTLA-4 is constitutively expressed on CD4+ T REG 8,9 and Wing et al. 8 reported that T REG -specific CTLA-4 deficiency impaired in vivo and in vitro suppressive function of T REG , and also produced potent tumour immunity. Regarding the effect of CTLA-4 blockade on T REG, Kavanagh et al. 6 showed that treatment with CTLA-4 antibodies in patients with Conversely, Simpson et al. 7 reported that treatment with an anti-CTLA-4 antibody induces a selective depletion of T REG within the tumour lesions in a mouse model of melanoma.
Regulatory T cells-an important target for cancer immunotherapy
On the basis of the different effects that immune checkpoint blockade can have on T REG function, it is possible that circum venting the activity of T REG might represent an important step to overcome some of the obstacles that, so far, have prevented the complete exploitation of the immuno therapy potential for the successful treatments of many cancers, including melanoma. 3 A substantial number of T REG , in tumour tissues and peripheral blood specific ally express C-C chemokine receptor 4 (CCR4), therefore, treatment with anti-CCR4 monoclonal antibody can evoke and augment antitumour immunity in patients with melanoma by selectively depleting or inhibiting T REG from the tumour tissue. 10, 11 The combinations of CTLA-4 and PD-1 or PD-L1 blockade showed an increased antitumour immunity compared with using each antibody alone; 1 however, an alternative combination strategy could include both immune checkpoint blocking antibodies and T REG -depleting molecules. For example, depletion of T REG by intraperitoneal administration of interleukin-2 diphtheria toxin followed by sequential PD-1 or PD-L1 blockade showed superior efficacy for eradication of acute myeloid leukaemia in a mouse model than did PD-1 or PD-L1 blockade alone. 12 Furthermore, Goding et al. 13 demonstrated that either blockade of the PD-1 pathway with anti-PD-L1 antibodies or depletion of tumour-specific T REG alone did not prevent tumour recurrence in a mouse model of melanoma. However, the combination of PD-L1 blockade and intumour T REG depletion via administration of interleukin-2 diphtheria toxin effectively mediated melanoma regression. 13 These results indicate that primary and relapsing cancer might have different characteristics and the use of combined immunotherapy approaches that specifically target T REG cells, could be required for highly resistant r ecurrent disease.
Overall, we believe that the effect of immune checkpoint blockade (via CTLA-4, PD-1 or PD-L1) on T REG should be considered when evaluating the efficacy of cancer-immunotherapy and that the available data clearly warrant clinical studies of combined immune checkpoint blockade and a T REG -targeting strategy in primary and relapsed cancers.
